3 Valuable Takeaways from the ANGEL-REBOOT Trial for ICAS-O Stroke
Stroke AHA/ASA Journal posted on X:
”In the secondary analysis of the ANGEL-REBOOT trial, longer puncture-to-recanalization time was associated with an increased risk of early reocclusion, while general anesthesia and eTICI 2c-3 were associated with a reduced risk of early reocclusion.”
Read the full article here.
ANGEL-REBOOT trial yields important clinical facts!
The findings were published in the research article ”Factors Associated With Early Reocclusion in Recanalized Intracranial Atherosclerotic Occlusion: ANGEL-REBOOT Insights” in Stroke, with following conclusions:
- In patients with intracranial atherosclerotic occlusion (ICAS-O) stroke, early reocclusion after successful mechanical thrombectomy is linked to poor outcomes.
- A post hoc analysis from a multicenter trial identified that longer puncture-to-recanalization time increases the risk of early reocclusion within 24 hours.
- Conversely, general anesthesia and achieving a postprocedural eTICI score of 2c-3 were associated with a lower risk.
These findings offer valuable insights for optimizing procedural strategies to improve outcomes in ICAS-O stroke.
Hemostasis Today, your daily update on the latest scientific advancements on the field of stroke management.
-
Oct 20, 2026, 05:46Jan T. Kielstein: DNP Poisoning and Hemoadsorption The Limits of Rescue Therapy
-
Oct 20, 2026, 05:33Giulia Di Paolo: Connecting Plasma Donation to the Patients Who Depend on It
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe LippiÖ‰ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question
-
Oct 20, 2026, 04:04Sadia Kamal: Honored to Receive the Outstanding Abstract Award at the 20th Midwest Platelet Conference
-
Oct 20, 2026, 04:03Yu-Hsuan Chen: One Antibody, Two Diseases from FcRn Biology to Clinical Translation
-
Oct 20, 2026, 03:49Domenico Simone Castiello: Rethinking Prolonged DAPT in Multivessel PCI – Insights from the DAPT-MVD Trial